115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and pharmacodynamic biomarker results from porter, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Galsky, M.; Autio, K.; Wentzel, K.; Graff, J.; Friedlander, T.; Densmore, J.; Cabanski, C.; Shotts, K.; Howes, T.; Yu, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade
    Meeting Abstract

    Nabet, B.; Hamidi, H.; Banchereau, R.; Morris, S.; Adler, L.; Srivastava, M.; Patil, N.; Gay, C.; Minna, J.; Heymach, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
    Meeting Abstract

    Bortone, D.; Monette, A.; Tschernia, N.; Cogdill, A.; Najjar, Y.; Sweis, R. F.; Valpione, S.; Wennerberg, E.; Bommareddy, P.; Haymaker, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
    Meeting Abstract

    Afeyan, A.; Oliveira, G.; Egloff, A. M.; Zeng, Z.; Chernock, R.; Zhou, L.; Messier, C.; Lizotte, P.; Wolff, J.; Pfaff, K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): A matched cohort study from the International Catch-It Consortium
    Meeting Abstract

    El Zarif, T.; Nassar, A.; Adib, E.; Fitzgerald, B.; Huang, J.; Mouhieddine, T.; Nonato, T.; McKay, R.; Li, M.; Mittra, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Development of optimized car T cells for therapy of glioblastoma
    Meeting Abstract

    Khan, J.; Cai, W.; Yang, Y.; Dong, L.; Hopland, K.; Yu, K. K. H.; Freeman, R.; Purdon, T.; Tabar, V.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immunometabolic modulation of engineered iPSC-NK cells for immunotherapy of solid tumors
    Meeting Abstract

    Borde, S.; Matosevic, S.; Lupo, K.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immunogenic landscape and therapeutic targeting of mutant NRAS "public" neoantigens
    Meeting Abstract

    Etxeberria, I.; Banks, L.; Chandran, S.; Correa, A.; Novak, B.; Fleischman, J.; Drilon, A.; Wolchok, J.; Merghoub, T.; Klebanoff, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Cd8+Foxp3+cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
    Meeting Abstract

    Cohen, E.; Wang, D.; Engle, E.; Green, B.; Caushi, J.; Zhang, J.; Sunshine, J.; Uttam, S.; Fotheringham, M.; Fiorante, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Garassino, M. C.; Le, X.; Iam, W. T.; Felip, E.; Sakai, H.; Veillon, R.; Smit, E. F.; Mazieres, J.; Raskin, J.; Cortot, A. B.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save